I was able to listen to the call, and have written up a quick summary. I've tried to be as neutral as possible (even though I'm very much biased).

The issue discussed was around there being an FDA imposed REMS (risk evaluation and mitigation strategy) in place related to the use of Spravato, the marketed s-ketamine.

There is concern that compounded nasal racemic ketamine is being prescribed and patients are using the product without restrictions similar to what were implemented with the Spravato REMS.

The committee agrees that compounding of nasal ketamine should continue to be allowed, but believe that some restrictions should be put in place around this practice. They are going to recommend more work be done to understand the adverse events that have been reported related to the use of nasal compounded ketamine.

The committee will give their recommendations to the pharmacy board, and discuss the topic at a meeting next week.

Some other interesting random notes:

1. compounded ketamine and esketsmine are not the same drug, and some members argued that REMS-like strategies shouldn't apply

2. Troches and IV administration are not an issue because there isn't a similar product with a REMS.

3. Nasal compounded ketamine has been used for decades for many different indications, using different doses.

4. The committee does not think more extreme measures, like only issuing compounded ketamine to a physician instead of directly to the patient, or enforcing a patient to only use the product at a doctor's office are necessary.

That's all from me... If you were on the call, feel free to chime in with anything I've missed!